The Hydration Pharmaceuticals Company Limited Stock

Equities

HPC

AU0000187957

Pharmaceuticals

Market Closed - Australian S.E. 21:10:58 2024-05-01 EDT 5-day change 1st Jan Change
0.015 AUD +15.38% Intraday chart for The Hydration Pharmaceuticals Company Limited +25.00% -37.50%

Financials

Sales 2022 9.1M 13.77M 12.45M Sales 2023 10.04M 15.2M 13.74M Capitalization 4.33M 6.56M 5.93M
Net income 2022 -10M -15.13M -13.68M Net income 2023 -8M -12.11M -10.95M EV / Sales 2022 0.99 x
Net cash position 2022 976K 1.48M 1.34M Net Debt 2023 2.05M 3.11M 2.81M EV / Sales 2023 0.64 x
P/E ratio 2022
-0.93 x
P/E ratio 2023
-0.39 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 69.37%
More Fundamentals * Assessed data
Dynamic Chart
The Hydration Pharmaceuticals' Revenue Falls 14% in March Quarter MT
The Hydration Pharmaceuticals Co. Secures AU$1.7 Million in Funding from Variation of Facility Agreement MT
The Hydration Pharmaceuticals Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10,387,823 Options of The Hydration Pharmaceuticals Company Limited are subject to a Lock-Up Agreement Ending on 14-DEC-2023. CI
17,482,735 Ordinary Shares of The Hydration Pharmaceuticals Company Limited are subject to a Lock-Up Agreement Ending on 14-DEC-2023. CI
6,671,720 Ordinary Shares of The Hydration Pharmaceuticals Company Limited are subject to a Lock-Up Agreement Ending on 10-DEC-2023. CI
The Hydration Pharmaceuticals Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023 CI
The Hydration Pharmaceuticals Posts 24% Jump in Q2 Net Sales MT
The Hydration Pharmaceuticals Achieves Daily Retail Sales Milestone on Amazon Canada MT
9,568,677 Ordinary Shares of The Hydration Pharmaceuticals Company Limited are subject to a Lock-Up Agreement Ending on 10-JUN-2023. CI
The Hydration Pharmaceuticals Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
The Hydration Pharmaceuticals Sees Record High Sales of $1 Million in January MT
The Hydration Pharmaceuticals Company Limited Announces Unaudited Sales Results for the Month of January 2023 CI
The Hydration Pharmaceuticals Company Limited Announces Executive Changes CI
More news
1 day+15.38%
1 week+25.00%
Current month+25.00%
3 months-16.67%
6 months-44.44%
Current year-37.50%
More quotes
1 week
0.01
Extreme 0.012
0.02
1 month
0.01
Extreme 0.012
0.02
Current year
0.01
Extreme 0.012
0.03
1 year
0.01
Extreme 0.012
0.07
3 years
0.01
Extreme 0.012
0.40
5 years
0.01
Extreme 0.012
0.40
10 years
0.01
Extreme 0.012
0.40
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-12-31
Director of Finance/CFO - 18-04-30
Corporate Secretary - 23-02-07
Members of the board TitleAgeSince
Director/Board Member 51 22-02-07
Director/Board Member - 18-10-14
Chairman - 21-11-01
More insiders
Date Price Change Volume
24-05-02 0.015 +15.38% 114,241
24-05-01 0.013 +8.33% 415,738
24-04-29 0.012 0.00% 45,000

Delayed Quote Australian S.E., May 01, 2024 at 09:10 pm

More quotes
The Hydration Pharmaceuticals Company Limited is an Australia-based hydration solutions company. The Company is focused on the sale and distribution of Hydralyte, which includes a product range of electrolyte-rich tablets, liquids, and powders. The Company markets and sells a range of liquid, tablet, and powder healthy hydration solutions products in the North American markets of Canada and the United States, under the Hydralyte brand. The Company operates as a wholesale supplier and online retailer of Hydralyte products in North America. The Company has a sales footprint in various markets, including the United States, Canada, China, and the United Kingdom. Its subsidiaries include Hydration Pharmaceuticals Trust, Hydration Pharmaceuticals Canada, Hydralyte LLC, and others.
Calendar
More about the company